DHL Group Invests in Pharma Logistics
Analysis based on 6 articles · First reported Apr 05, 2026 · Last updated Apr 05, 2026
The significant investment by DHL Group in pharmaceutical logistics is expected to boost the logistics and pharmaceutical sectors, providing more resilient supply chains amid global disruptions. This move also reflects a broader trend of drug companies outsourcing logistics, which could lead to increased efficiency and focus on core research and production, positively impacting the market.
DHL Group plans to invest 2 billion euros in pharmaceutical logistics worldwide by 2030, with half allocated to North America and a quarter to Europe. This investment aims to double the revenue of its pharmaceutical logistics division to 10 billion euros within five years, helping to offset losses from declining mail services and trade disruptions caused by conflicts and tariff wars. The move is also influenced by European drugmakers relocating production to the United States due to former President Donald Trump's tariffs and efforts to lower drug prices. The global pharmaceutical market is projected to exceed $2.6 trillion by 2030, driven by the United States and emerging markets, with cancer and weight management treatments showing high growth prospects. The investment addresses the fragility of global supply chains, which have been shaken by war, pandemics, and trade chaos, ensuring reliable delivery of crucial medical products.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard